Levobupivacaine inhibits lipopolysaccharide-induced high mobility group box 1 release in vitro and in vivo.
J Surg Res
; 192(2): 582-91, 2014 Dec.
Article
em En
| MEDLINE
| ID: mdl-25017707
ABSTRACT
BACKGROUND:
The aim of the study was to investigate whether levobupivacaine (LB) suppressed lipopolysaccharide (LPS)-induced high mobility group box 1 (HMGB1) release in vitro and in vivo, and to determin its molecular mechanisms of action. MATERIALS ANDMETHODS:
RAW264.7 cells were treated with LPS and LB for 24 h. Levels of HMGB1, nuclear factor-kappa B (NF-κB) and phosphorylated p38 mitogen-activated protein kinase (MAPK) were measured by Enzyme-linked immunosorbent assay and Western blotting; the levels of HMGB1 messenger RNA were measured by real-time polymerase chain reaction. In addition, cecal ligation and puncture-induced septic C57BL/6 received LB infusion, and the levels of HMGB1 and functional parameters of multiple organs determined using several detection kits.RESULTS:
LB inhibited HMGB1 release in vitro and in vivo. Furthermore, LB inhibited the translocation of NF-κB and phosphorylation of p38 MAPK in vitro. Mice treated with LB infusion improved survival in mice and significantly reduced cecal ligation and puncture-induced dysfunction of organs.CONCLUSIONS:
LB suppresses LPS-induced HMGB1 release in vitro and in vivo by partially inhibiting NF-κB/p38 MAPK pathways. LB can rescue mice from sepsis and protect against organ dysfunction in septic mice.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Bupivacaína
/
Lipopolissacarídeos
/
Sepse
/
Proteína HMGB1
/
Anestésicos Locais
/
Macrófagos
Limite:
Animals
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article